PCSK9 is a co-activator of platelet function beyond its role in cholesterol homeostasis

(European Society of Cardiology) PCSK9 is a co-activator of platelet function beyond its role in cholesterol homeostasis, according to research presented at ESC Congress today. The findings suggest that PCSK9 inhibitors, a new class of cholesterol-lowering treatments, may also reduce thrombosis by interfering with platelet activation.